IN THE CLAIMS

 (Currently Amended) A method for modulating preventing a transplantationassociated immune response in a subject, comprising:

administering to [[a]]said subject in need of an effective amount of a conjugate comprising a earboxyl group containing organic compound methotrexate and albumin at a methotrexate:albumin molar ratio of 1:1000 to 2:1[[,]]

wherein said carboxyl group-containing organic compound is a cytostatic or an immunosuppressant.

- 2. (Canceled)
- (Currently Amended) The method of claim 1, wherein said transplantation-associated immune response is graft versus host disease (GVHD).
- (Previously Amended) The method of claim 3, wherein said GVHD is an acute GVHD.
- (Previously Amended) The method of claim 3, wherein said GVHD is a chronic GVHD.
- (Previously Amended) The method of claim 1, wherein said transplantation is a bone marrow transplantation.
- (Previously Amended) The method of claim 1, wherein said transplantation is an
 organ transplantation.
- (Previously Amended) The method of claim 1, wherein said transplantation is an allogeneic transplantation.
 - 9-11. (Canceled)

- 12. (Previously Amended) The method of claim 1, wherein said albumin is human albumin
- (Previously Amended) The method of claim 1, wherein said albumin is a native human albumin.
 - 14. (Canceled).
- 15. (Currently Amended) A method for preparing a conjugate comprising a earboxyl group-containing organic compound methodrexate and albumin, said method comprising:

activating said earboxyl group containing organic compound methotrexate with 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide in an organic solvent; and

reacting activated earboxyl group-containing organic compound methotrexate with albumin at a methotrexate: albumin molar ratio of 10:1 to 1:10[[,]]

wherein said carboxyl group containing organic compound is a cytostatic or an immunosuppressant.

- 16-19. (Canceled)
- 20. (Currently Amended) The method of claim 15, wherein said earboxyl groupcontaining organic compound methotrexate is activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in an anhydrous organic solvent by heating.
- (Currently Amended) The method of claim [[8]]7, wherein said organ transplantation is selected from the group consisting of kidney, heart and liver transplantation.
- (Currently Amended) The method of claim [[18]]15, wherein said methotrexate is reacted with albumin at a methotrexate: albumin molar ratio of 1.5:1 to 1:1.5.